

DFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 22, 2007

Signature:

Dawn Class
(DAWN CLASS)

Docket No.: AREX-P01-010
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Schultes et al.

Confirmation No.: 3995

Application No.: 10/531,849

Art Unit: 1644

Filed: July 15, 2005

For: THERAPEUTIC ADJUVANT

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. § 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 C.F.R. § 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in a Supplemental Partial European Search Report mailed on March 1, 2007, during the prosecution of European Patent Application No. EP 03 77 7662, which corresponds to the above referenced application, and in accordance with 37 C.F.R. §§ 1.97(c) and (b)(3), hereby submits these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Supplemental Partial European Search Report and of each document required under 37 C.F.R. § 1.98(a)(2) cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such


document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. § 1.97(b)(3)).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. **18-1945**, under Order No. **AREX-P01-010**.

Dated: May 22, 2007

Respectfully submitted,



Yu Lu, Ph.D., J.D.

Registration No.: 50,306
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/531,849		
		Filing Date	July 15, 2005		
		First Named Inventor	Birgit C. Schultes		
		Art Unit	1644		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	AREX-P01-010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AN	US-20020048583-A1	04-25-2002	Schultes et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CB	BAUM et al., "Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13," Hybridoma, 12(5):583-589, (1993).		
	CC	BLOSS et al., "OVAREX™ MAb: A Low Dose Xenotypic Antibody Approach to Ovarian Cancer Immunotherapy," Cancer Investigation, 18(1):72, (1999).		
	CD	QI et al., "Factors to Consider in Antibody-Based Immunotherapy of Cancer," Proceedings of the Annual Meeting of the American Association for Cancer Research, 41:290 (Abstract) (2000).		
	CE	SCHLEBUSCH et al., "A Monoclonal Antidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer," Hybridoma, 14(2):167-174, (1995).		
	CF	SCHULTES et al., "Immunotherapy of Human Ovarian Carcinoma with OVAREX™ MAb-B43.13 in a Human PBL-SCID/BG Mouse Model," Hybridoma, 18(1):47-55, (1999).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--